TAO Synergies Inc. Files 8-K: Director Changes & Officer Appointments

TL;DR

TAO Synergies Inc. 8-K: Board shakeup and new execs filed 12/19.

AI Summary

TAO Synergies Inc. filed an 8-K on December 19, 2025, reporting on events from December 18, 2025. The filing covers the departure of directors, election of new directors, appointment of officers, and details on compensatory arrangements. It also includes information on matters submitted to a vote of security holders and financial statements/exhibits.

Why It Matters

This 8-K filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.

Risk Assessment

Risk Level: medium — Changes in directors and officers, along with compensatory arrangements, can indicate internal shifts that may carry associated risks.

Key Numbers

• 001-40458 — SEC File Number (Identifies the company's filing with the SEC.)
• 461585656 — EIN (Employer Identification Number for TAO Synergies Inc.)
• 20251218 — Earliest Event Date (The date of the earliest event reported in the 8-K.)

Key Players & Entities

• TAO Synergies Inc. (company) — Registrant
• Synaptogenix, Inc. (company) — Former Company Name
• NEUROTROPE BIOSCIENCE, INC. (company) — Former Company Name
• Delaware (jurisdiction) — State of Incorporation

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share TAOX The Nasdaq

Filing Documents

• tm2533681d1_8k.htm (8-K) — 40KB
• tm2533681d1_10-1.htm (EX-10.1) — 126KB
• 0001104659-25-123187.txt ( ) — 359KB
• snpx-20251218.xsd (EX-101.SCH) — 3KB
• snpx-20251218_lab.xml (EX-101.LAB) — 33KB
• snpx-20251218_pre.xml (EX-101.PRE) — 22KB
• tm2533681d1_8k_htm.xml (XML) — 4KB

02. Departure of Directors or Certain Officers; Election

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) At the Annual Meeting (as defined below) of TAO Synergies Inc. (the "Company"), stockholders approved an amendment and restatement of the Company's 2020 Equity Incentive Plan (as amended and restated, the "Amended and Restated Equity Incentive Plan") to increase the number of shares of common stock ("Common Stock") reserved for issuance thereunder by 500,000 shares to 3,175,000 shares. The foregoing description of the Amended and Restated Equity Incentive Plan does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated Equity Incentive Plan, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K (the "Current Report") and incorporated herein by reference.

07. Submission of Matters to a Vote

Item 5.07. Submission of Matters to a Vote of Security Holders. On December 18, 2025, the Company held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the holders of 3,318,341 shares of the Company's Common Stock, or approximately 43.18% of the Company's outstanding shares of Common Stock, were represented in person or by proxy and, therefore, a quorum was present. At the Annual Meeting, the Company's stockholders considered five proposals, which are described briefly below and in more detail in the proxy statement. The final voting results for each proposal are set forth below. Proposal 1 – Election of Directors The Company's stockholders voted to elect one director, Bruce T. Bernstein, to hold office until the 2028 annual meeting of stockholders, and until his successor is elected and qualified, by the following votes: Nominee Shares Voted For Shares Voted Against Abstentions Bruce T. Bernstein 1,040,943 74,437 12,198 Proposal 2 - Approval of the Issuance of Common Stock Underlying Shares of Convertible Preferred Stock and Warrants The Company's stockholders voted to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock underlying shares of convertible preferred stock and warrants issued by the Company pursuant to the terms of (a) that certain Securities Purchase Agreement, dated October 13, 2025, by and among the Company and the investors named therein and (b) that certain engagement letter by and among the Company and GP Nurmenkari Inc. as placement agent, in an amount equal to or in excess of 20% of the Company's Common Stock outstanding before the issuance of such convertible preferred stock and warrants (including upon the operation of anti-dilution provisions contained in such convertible preferred stock and warrants), by the following votes: Shares Voted For Shares Voted Against Abstentions 504,481 78,798 2,109 Proposal 3 – Approval

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Amended and Restated TAO Synergies Inc. 2020 Equity Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant hass duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TAO SYNERGIES INC. Date: December 19, 2025 By: /s/ Robert Weinstein Name: Robert Weinstein Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR